HeRO® Graft Clinical Performance

Understand the clinical data and outcomes of HeRO Graft.
Understand the clinical data and outcomes as Dr. Jeffrey H. Lawson and Shawn M. Gage, PA–C discuss the published data on HeRO Graft.

Fewer infections: 69% reduced infection rate compared with catheters1

Superior Dialysis Adequacy: 1.7Kt/V, a 16% to 32% improvement compared with catheters1

High Patency Rates: Up to 87% cumulative patency at 2 years1,2

Cost Savings: A 23% average savings per year compared with catheters3

Clinical Outcomes

  HERO GRAFT
GAGE, ET AL. EJVES2		 HERO GRAFT
KATZMAN, ET AL. JVS1		 CATHETER LITERATURE1 AV GRAFT LITERATURE1
BACTEREMIA RATES
(INFECTIONS/1,000 DAYS)		 0.14 0.70 2.3 0.11
ADEQUACY OF DIALYSIS
(MEAN KT/V) §		 N/A 1.7 1.29 – 1.46 1.37 – 1.62
CUMULATIVE PATENCY
(AT 1 YEAR)		 91% 72%ǂ 37% 65%
INTERVENTION RATE
(PER YEAR)
 1.5 2.5 5.8 1.6 – 2.4

 

§ Note: Every 0.1 decrease in Kt/V increases the mortality rate by 7%4 and is significantly (P<0.05) associated with 11% more hospitalizations, 12% more hospital days, and a $940 increase in Medicare inpatient expenditures.5

ǂ 8.6 months

References

  1. Katzman, MD, et al., J Vasc Surg 2009.
  2. Gage et al., EJVES 2012.
  3. Dageforde et al., JSR 2012.
  4. Dhingra et al., Kidney Int 2001.
  5. 2006 NKF KDOQI, Guideline 4.